Unknown

Dataset Information

0

Trial watch: Peptide-based vaccines in anticancer therapy.


ABSTRACT: Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppression. Several strategies have been developed to overcome such limitations, including the use of immunostimulatory adjuvants, the co-treatment with cytotoxic anticancer therapies that enable the coordinated release of damage-associated molecular patterns, and the concomitant blockade of immune checkpoints. Personalized peptide-based vaccines are also being explored for therapeutic activity in the clinic. Here, we review recent preclinical and clinical progress in the use of peptide-based vaccines as anticancer therapeutics.Abbreviations: CMP: carbohydrate-mimetic peptide; CMV: cytomegalovirus; DC: dendritic cell; FDA: Food and Drug Administration; HPV: human papillomavirus; MDS: myelodysplastic syndrome; MHP: melanoma helper vaccine; NSCLC: non-small cell lung carcinoma; ODD: orphan drug designation; PPV: personalized peptide vaccination; SLP: synthetic long peptide; TAA: tumor-associated antigen; TNA: tumor neoantigen.

SUBMITTER: Bezu L 

PROVIDER: S-EPMC6279318 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications


Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppres  ...[more]

Similar Datasets

| S-EPMC4485775 | biostudies-literature
| S-EPMC3525611 | biostudies-literature
| S-EPMC3902120 | biostudies-literature
| S-EPMC4485755 | biostudies-literature
| S-EPMC4292311 | biostudies-literature
| S-EPMC4904962 | biostudies-literature
| S-EPMC3654598 | biostudies-literature
| S-EPMC4008456 | biostudies-literature
| S-EPMC4905370 | biostudies-literature
| S-EPMC5543823 | biostudies-literature